je.st
news
Tag: hepatitis
Texas Medicaid holds off on proposed limits for Gilead hepatitis drug
2014-04-11 23:59:42| Biotech - Topix.net
Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.
Tags: texas
drug
proposed
limits
Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
2014-04-11 07:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Initiation of C-EDGE Phase 3 Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: activity
combination
patients
therapy
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
2014-04-10 13:18:10| Biotech - Topix.net
Gilead Sciences, Inc. today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir for the treatment of chronic hepatitis C virus infection.
Tags: c
results
treatment
phase
WHO joins clamor to make new hepatitis C pills affordable
2014-04-10 08:13:18| Biotech - Topix.net
The World Health Organization wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.
Tags: make
affordable
joins
pills
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection
2014-04-10 07:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
studies
patients
Sites : [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] next »